Aligos Therapeutics (ALGS) Net Cash Flow (2019 - 2026)

Aligos Therapeutics has reported Net Cash Flow for 8 years, with the latest figure at $11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 68.07% year-over-year to $11.7 million; the trailing twelve-month figure through Mar 2026 stood at -$43.7 million (down 188.31% YoY), and the FY2025 full-year result was -$18.7 million, up 81.05% from the prior year.
• Net Cash Flow for Q1 2026 stood at $11.7 million, up from -$23.6 million in the prior quarter.
• The five-year high for Net Cash Flow was $65.3 million in Q4 2023, with the low at -$111.4 million in Q1 2024.
• Historically, Net Cash Flow has averaged -$9.2 million across 5 years, with a median of -$2.4 million in 2023.
• Annual changes were most pronounced in 2023 — Net Cash Flow jumped 1390.45% — and 2024, when it tumbled 4551.65%.
• Aligos Therapeutics' Net Cash Flow stood at -$5.1 million in 2022, then jumped by 1390.45% to $65.3 million in 2023, then sank by 97.45% to $1.7 million in 2024, then sank by 1519.15% to -$23.6 million in 2025, then jumped by 149.66% to $11.7 million in 2026.
• The last three Net Cash Flow figures came in at $11.7 million (Q1 2026), -$23.6 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.